|
Real-time Estimate
Cboe BZX
10:19:47 2026-10-05 EDT
|
5-day change | 1st Jan Change | ||
| 3.545 USD | -0.98% |
|
-11.58% | +122.98% |
| 08-17 | B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating | MT |
| 08-13 | MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 228M | - | - | - | ||
| 74.16B | |||||
| 57.39B | |||||
| 47.64B | |||||
| 44.29B | - | - | - | - | - |
| 42.5B |
- Stock Market
- Stocks
- MGNX Stock
- Charts MacroGenics, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
